Precision Medicine: MRI-Guided Stereotactic Ablative Radiotherapy (MRI-SABR) for Early-Stage Glottic Laryngeal Cancer

This trial is testing MRI-guided stereotactic ablative radiotherapy (MRI-SABR) — a highly precise form of radiation therapy — for early-stage glottic laryngeal cancer (cancer of the vocal cords). The goal is to deliver radiation more accurately to the tumor while protecting surrounding healthy tissue, potentially preserving the patient's voice and quality of life. **You may be eligible if...** - You are 18 or older - You have been diagnosed with squamous cell carcinoma of the vocal cords (glottic larynx), confirmed by biopsy - Your cancer is early stage (T1–T2, no lymph node involvement) - Your general health is reasonably good (ECOG score 0–2) - You are able to understand Lithuanian and complete questionnaires **You may NOT be eligible if...** - Your cancer is at an advanced stage (stage III–IV) - You have previously had radiation therapy for head and neck cancer - You are pregnant or breastfeeding - You have another active cancer - You have serious uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.